Regeneron Pharmaceuticals. has been granted a patent for methods and compositions that enable the generation of fertile XY female animals. The techniques involve silencing specific regions of the Y chromosome and utilizing feminizing media to enhance the production of these animals from XY pluripotent or totipotent cells. GlobalData’s report on Regeneron Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Regeneron Pharmaceuticals, Transgenic murine models was a key innovation area identified from patents. Regeneron Pharmaceuticals's grant share as of June 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
Generating fertile xy female animals using modified embryonic stem cells
The granted patent US12041918B2 outlines a method for selecting donor mouse XY embryonic stem (ES) cells aimed at producing fertile, phenotypically female XY mice. The process begins with culturing a population of mouse XY ES cells in a low-osmolality medium that maintains their pluripotency. This medium contains sodium bicarbonate at a concentration of 18 mM to 26 mM and has an osmolality ranging from 216 mOsm/kg to 322 mOsm/kg. The method involves assaying the cultured cells for mRNA expression levels of specific genes (Ddx3y, Uty, and Eif2s3y) and selecting the cell with the lowest expression of these genes, which is crucial for generating a fertile, phenotypically female XY mouse. The patent specifies that the selected donor cell should exhibit at least a 90% reduction in mRNA expression compared to a control cell.
Further claims detail additional parameters of the method, including the duration of culturing the ES cells, the specific strains of mice from which the cells may originate, and the potential for targeted genetic modifications. The method also encompasses the introduction of the selected donor XY ES cell into a mouse host embryo, followed by gestation in a recipient female mouse to produce F0 XY mouse progeny. The patent emphasizes that the resulting F0 phenotypically female XY mouse should be fertile and capable of producing progeny, with specific breeding strategies outlined to ensure the desired genetic traits in subsequent generations. Overall, the patent presents a comprehensive approach to manipulating mouse genetics for research and breeding purposes, particularly in the context of sex determination and fertility.
To know more about GlobalData’s detailed insights on Regeneron Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
